News Releases

• 17/01/22

  Ryvu Therapeutics appoints Hendrik Nogai, M.D. as Chief Medical Officer

  Read more
• 03/01/22

  Ryvu Therapeutics to participate in the LifeSci Partners 11th Annual Corporate Access Event and H.C. Wainwright Bioconnect Conference

  Read more
• 14/12/21

  Ryvu announces option to license inflammation program exercised by Galapagos NV

  Read more
• 13/12/21

  Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology Annual Meeting and the 44th San Antonio Breast Cancer Symposium

  Read more
• 10/11/21

  Ryvu Therapeutics Reports Q3 2021 Financial Results

  Read more
• 09/11/21

  Ryvu Therapeutics to Highlight HPK1 and STING Programs at the Upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

  Read more
• 04/11/21

  Ryvu Therapeutics & Collaborators to Present Clinical and Translational Data from RVU120 and SEL24/MEN1703 at the 63rd ASH Annual Meeting & Exposition and the 44th Annual SABCS

  Read more
• 07/10/21

  Ryvu Therapeutics co-runs Drug Discovery and Development MSc degree, at the Faculty of Pharmacy, Jagiellonian University

  Read more
• 08/09/21

  Ryvu Therapeutics Reports 2021 Half-Year Financial Results

  Read more
• 25/08/21

  Ryvu Announces First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors and CMO Transition

  Read more
• 18/08/21

  Ryvu Therapeutics publishes MCT4 inhibitors research paper in the Journal of Medicinal Chemistry

  Read more
• 03/08/21

  Ryvu Therapeutics to participate in upcoming global investor conferences

  Read more
• 14/07/21

  FDA lifts Partial Clinical Hold on Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

  Read more
• 11/06/21

  Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual EHA Congress. Phase I/II Data for SEL24 (MEN1703) presented by development partner Menarini.

  Read more
• 10/06/21

  Representatives of the Ministry of Economic Development, Labour and Technology visited Ryvu Therapeutics

  Read more
• 10/06/21

  Ryvu Therapeutics among the founding members of 30% Club Poland

  Read more
• 09/06/21

  Discussion On Ryvu Data Presented at EHA 2021 – Conference Call

  Read more
• 02/06/21

  Synthetic lethality in cancer treatment – Ryvu Therapeutics seminar

  Read more
• 01/06/21

  SEL24 (MEN1703) Clinical Data from DIAMOND-01 Trial to be Presented at ASCO and EHA Virtual Meetings 2021

  Read more
• 28/05/21

  Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland

  Read more
• 18/05/21

  Ryvu Therapeutics announces participation in the UBS 2021 Global Healthcare Virtual Conference and the Erste Group Innovation Conference 2021

  Read more
• 14/05/21

  Ryvu Therapeutics presents at STING- & TLR-Targeting Therapies Summit

  Read more
• 12/05/21

  Ryvu Therapeutics to Present Clinical and Translational Data from RVU120 at the Virtual 26th Annual Congress of the European Hematology Association. New clinical abstract on SEL24(MEN1703) also available.

  Read more
• 12/05/21

  Ryvu Therapeutics Reports First Quarter 2021 Financial Results

  Read more
• 26/04/21

  Ryvu Therapeutics appoints Vatnak Vat-Ho as Chief Business Officer

  Read more
• 08/04/21

  Ryvu Announces Partial Clinical Hold of Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

  Read more
• 18/03/21

  Ryvu Therapeutics at BIO-Europe Spring

  Read more
• 16/03/21

  Ryvu Therapeutics reports financial results for 2020

  Read more
• 16/03/21

  Ryvu Therapeutics awarded in the Stock Exchange Company of the Year competition

  Read more
• 11/03/21

  Ryvu Therapeutics to Present Recent Data from Multiple Oncology Programs at AACR 2021 Virtual Annual Meeting

  Read more
• 18/01/21

  Ryvu Therapeutics project regarding Phase I/II clinical study of SEL120 (RVU 120) in solid tumors recommended for financing by NCBiR

  Read more
• 07/01/21

  Ryvu Therapeutics to expand its Phase I study of SEL120 (RVU120) in patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome to Poland

  Read more
• 04/01/21

  Ryvu Therapeutics has submitted a new Clinical Trial Application for the conduct of a Phase I/II study of RVU120 (SEL120) in patients with solid tumors

  Read more
• 21/12/20

  "Dream with Ryvu" - a corporate movie by Ryvu Therapeutics

  Read more
• 03/12/20

  Ryvu Therapeutics publishes MNK1/2 kinase inhibitors research paper in the European Journal of Medicinal Chemistry

  Read more
• 01/12/20

  Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting

  Read more
• 26/11/20

  Solebury Trout Talks Podcast: Interview with Pawel Przewiezlikowski

  Read more
• 23/11/20

  Ryvu Therapeutics Appoints Kamil Sitarz as Chief Operating Officer and Member of the Management Board

  Read more
• 19/11/20

  Ryvu Therapeutics Reports Q3 2020 Financial Results

  Read more
• 12/11/20

  Ryvu Therapeutics at Jefferies Virtual London Healthcare Conference

  Read more
• 19/10/20

  Ryvu Therapeutics at BIO-Europe 2020

  Read more
• 15/10/20

  Ryvu Therapeutics Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting (SITC 2020)

  Read more
• 16/09/20

  First patient dosed in Europe within the Expansion Cohort of Phase I/II Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia

  Read more
• 15/09/20

  Ryvu Therapeutics Reports 2020 Half-Year Financial Results

  Read more
• 09/09/20

  Ryvu Therapeutics to present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference

  Read more
• 22/07/20

  Ryvu Therapeutics raised over USD 36 million from its share issue

  Read more
• 15/07/20

  The share issue price in Ryvu Therapeutics public offering set at PLN 60

  Read more
• 13/07/20

  Ryvu Therapeutics shareholders have approved a new share issue. Book-building starts today.

  Read more
• 10/06/20

  Ryvu Therapeutics Reports First Quarter 2020 Financial Results

  Read more
• 05/06/20

  Ryvu Therapeutics signs a grant agreement for the development of targeted immuno-oncology therapy

  Read more
• 03/06/20

  NodThera, Ryvu spin-off company, secures £44.5million ($54.5million) Series B Financing

  Read more
• 02/06/20

  Ryvu Therapeutics has completed the construction of the R&D Center for Innovative Drugs

  Read more
• 01/06/20

  Ryvu Therapeutics at BIO Digital 2020

  Read more
• 21/05/20

  Ryvu Therapeutics to Present at Jefferies 2020 Virtual Healthcare Conference

  Read more
• 18/05/20

  Ryvu Therapeutics to Present Recent Data from Multiple Oncology Programs at AACR 2020 Virtual Annual Meeting II

  Read more
• 14/05/20

  Ryvu Therapeutics announces availability of abstracts regarding Phase 1/2 study of SEL120 and SEL24/MEN1703 accepted for presentation at 25th EHA Congress

  Read more
• 16/04/20

  Galapagos and Ryvu announce research collaboration

  Read more
• 09/04/20

  Ryvu Therapeutics Reports Annual 2019 Financial Results

  Read more
• 31/03/20

  Ryvu Therapeutics To Present At Solebury Trout Virtual Investor Conference

  Read more
• 28/03/20

  Ryvu Therapeutics receives Orphan Drug Designation from FDA for SEL120 to treat Acute Myeloid Leukemia

  Read more
• 18/03/20

  Successful Completion of Phase I Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia

  Read more
• 17/03/20

  Ryvu Therapeutics at BIO-Europe Spring 2020

  Read more
• 05/03/20

  Ryvu Therapeutics to Present at the 32nd Annual ROTH Conference

  Read more
• 26/02/20

  Ryvu Therapeutics signs a grant agreement for the development of targeted oncology therapies based on the synthetic lethality concept

  Read more
• 20/01/20

  Ryvu Therapeutics scientists as co-authors of Merck poster presentation on HIF-2alpha inhibitors

  Read more
• 17/01/20

  Ryvu Therapeutics together with scientists from the Jagiellonian University publish a synthetic lethality research paper in Biomolecules

  Read more
• 06/11/19

  Ryvu Therapeutics Announces Presentations on CDK8 Inhibitor SEL120 at the 61st ASH Annual Meeting

  Read more
• 06/11/19

  Ryvu Therapeutics Reports Third Quarter 2019 Financial Results

  Read more
• 05/11/19

  Ryvu Therapeutics to Present at BIO-Europe 2019

  Read more
• 14/10/19

  Ryvu Therapeutics Appoints Chief Medical Officer Setareh Shamsili, M.D., Ph.D., to Executive Management Board

  Read more
• 03/10/19

  Ryvu Therapeutics Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)

  Read more
• 01/10/19

  Ryvu Therapeutics and Selvita Announce registration of Corporate Split by the National Court Register of Poland

  Read more
• 19/09/19

  Ryvu Announces Shareholder Approval of Corporate Split and New Name of Ryvu Therapeutics for Oncology Development Company

  Read more
• 06/09/19

  Ryvu Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

  Read more
• 03/09/19

  Polish Financial Supervision Authority Approves Selvita CRO Prospectus, Allowing Corporate Split into Two Separately Listed Companies to Proceed

  Read more
• 25/07/19

  Selvita Appoints Setareh Shamsili, M.D., Ph.D., as Chief Medical Officer

  Read more
• 24/07/19

  Selvita to Present at Upcoming Conferences in September

  Read more
• 16/05/19

  Selvita announces availability of abstracts regarding Phase 1/2 study of SEL24/MEN1703 accepted for presentation at 2019 ASCO Annual Meeting and 24th EHA Congress

  Read more
• 13/05/19

  Selvita to Present at the UBS 2019 Global Healthcare Conference in New York

  Read more
• 17/04/19

  Poster regarding Phase 1/2 study of SEL24/MEN1703 accepted for the ASCO 2019 Annual Meeting

  Read more
• 04/04/19

  Selvita to present at the 2019 HCW Global Life Sciences Conference in London

  Read more
• 28/03/19

  Selvita to Separate Oncology Therapeutics and Contract Research Business Units into Two Global Companies

  Read more
• 26/03/19

  Selvita Announces U.S. FDA Acceptance of Investigational New Drug Application to Commence Clinical Development of SEL120 in the Treatment of Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  Read more
• 04/03/19

  Selvita to Present Data from Multiple Oncology Programs at AACR 2019 Annual Meeting

  Read more
• 02/01/19

  Selvita to Present at Biotech Showcase 2019 in San Francisco

  Read more
• 21/11/18

  Selvita Announces Presentations on CDK8 Inhibitor SEL120 at the 60th American Society of Hematology Annual Meeting

  Read more
• 08/11/18

  Selvita to Present New Data from SEL120 Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

  Read more
• 31/10/18

  Selvita to present new data from its oncology programs at the upcoming SITC 2018

  Read more
• 03/10/18

  Selvita presents new data from SEL120 program during Leukemia and Lymphoma – Europe and the USA Linking Knowledge and Practice

  Read more
• 03/09/18

  Selvita presents at the 25th Annual BioCentury NewsMakers in the Biotech Industry

  Read more
• 27/08/18

  Selvita to present new data from its oncology programs at the 6th Annual Immuno-Oncology Summit

  Read more
• 26/04/18

  Institute of Hematology and Transfusion Medicine and Selvita publish joint research results on SEL24 potential in Chronic Lymphocytic Leukemia

  Read more
• 16/04/18

  Selvita publishes research results on SEL24 in Oncotarget

  Read more
• 06/04/18

  Selvita to present new data from its oncology programs at the upcoming AACR Annual Meeting 2018

  Read more
• 16/02/18

  Selvita Announces Successful Completion of $41 M Book Building

  Read more
• 16/12/17

  FDA lifts Clinical Hold on Selvita’s Phase I/II Clinical Trial with SEL24 in AML

  Read more
• 17/10/17

  Selvita researchers and academic collaborators demonstrate the potential of MNK1/2 kinase inhibitors in the treatment of c-Kit positive melanomas

  Read more
• 07/10/17

  Selvita Announces Full Clinical Hold on Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia

  Read more
• 03/10/17

  Selvita and Menarini present together at the European Business Development Conference

  Read more
• 08/08/17

  Selvita and The Leukemia & Lymphoma Society Announce Partnership to Advance SEL120 into Phase I for AML Patients

  Read more
• 13/07/17

  Institute of Hematology and Transfusion Medicine and Selvita publish joint research results in SEL24 project

  Read more
• 06/06/17

  Selvita presents at 18th Drug Discovery Summit in Berlin

  Read more
• 07/04/17

  Selvita researchers publish new paper on CDK8 inhibitor SEL120 in Oncotarget

  Read more
• 28/03/17

  Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24

  Read more
• 17/03/17

  Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia

  Read more
• 13/03/17

  Selvita to present new data from its oncology programs at the upcoming AACR Annual Meeting 2017

  Read more
• 13/02/17

  Selvita researchers publish MNK inhibitors review in Current Medicinal Chemistry

  Read more
• 16/12/16

  Selvita to present at Biotech Showcase 2017 in San Francisco

  Read more
• 30/11/16

  Selvita presents posters at 2016 EORTC-NCI-AACR Symposium

  Read more
• 18/08/16

  FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML

  Read more
• 18/08/16

  FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML

  Read more
• 28/07/16

  Epidarex Capital Creates Nodthera Limite

  Read more
• 06/06/16

  Selvita epigenetic project is the first Polish drug target program selected by EU Lead Factory

  Read more
• 01/02/16

  Selvita will present at the 18th Annual BIO CEO & Investor Conference 2016

  Read more
• 10/12/15

  Selvita wins the European Rising Star Award

  Read more
• 25/11/15

  The most recent data from Selvita’s SEL24 to be presented at the 57th ASH Annual Meeting & Exposition

  Read more
• 02/11/15

  Merck and Selvita Announce Drug Discovery Collaboration

  Read more
• 24/09/15

  Selvita launches new company – bioinformatics and personalized medicine focused Ardigen

  Read more
• 22/09/15

  H3 Biomedicine and Selvita Extend Precision Cancer Medicines Collaboration

  Read more
• 07/05/15

  Selvita receives the Economic Award of the President of Poland

  Read more
• 31/03/15

  Selvita initiates IND-enabling Studies for its first-in-class PIM/FLT3 inhibitor

  Read more
• 07/11/14

  Felicitex Therapeutics and Selvita initiate strategic collaboration to target cancer quiescence

  Read more
• 26/08/14

  Selvita and H3 Biomedicine will present at the Drug Discovery USA Congress 2014

  Read more
• 08/08/14

  New data from Selvita’s SEL24 will be presented by Institute of Hematology and Transfusion Medicine (IHT) at the ASH Meeting on Lymphoma Biology 2014

  Read more